Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy.
about
Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal TransitionNext-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignanciesLongitudinal tracking of single live cancer cells to understand cell cycle effects of the nuclear export inhibitor, selinexor.First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid TumorsPhase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis.Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compoundsNuclear transport factors: global regulation of mitosis.Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells.Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.Preclinical activity of selinexor, an inhibitor of XPO1, in sarcomaReverse the Resistance to PARP Inhibitors.Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.CRM1 Inhibitors for Antiviral Therapy.A "RANning" leap with "XPOrt" into TKI resistanceEGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer.Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy.XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignanciesDown-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression
P2860
Q27307611-20DC174B-0AF2-4346-8F4D-7D6D517C5706Q27712238-EC331AC2-EE33-4103-AD92-B0705E8D172AQ30665952-8AC88BCB-C698-41D9-B7AA-B92EF932ECFAQ33430367-2B75201A-13D8-4CD4-8FBC-AFE92CA9C2CEQ33434141-BCFE02CE-2BE1-4515-B33B-0E151E93287BQ33442836-AA3597CD-941B-46C5-ABE7-E994AB31BEF2Q35843010-95654DD0-CD51-4A5C-BEEE-B4D52D64C6D3Q35930449-5EF29DC2-0E3C-42CC-93B6-22615A652FE3Q36214313-E5F46F23-CECF-4D57-A456-98CDDCE1AFCBQ36642752-23BB4C12-0DE1-4E89-A5E1-FFB76D0532C8Q37086082-81939F9A-D4E8-46D3-B883-FF45823873BFQ37675896-35167AF5-6AD5-4D85-9BE4-FB355436F99DQ38738390-1A1DA55D-A6D3-4FB1-A50A-C29F8EAADA2DQ39431526-8A5D5A1D-3A5D-44D5-94B5-3A15E5A222B4Q42178391-346198F8-CDE9-427D-BE40-686963D2CCC2Q47111538-178A5571-F169-4DD1-8315-64C640179F62Q51157837-9CE2B713-842F-4BD6-AE21-A3567AA4C439Q57818336-4EAC692C-04CA-47D0-86AD-3ECB8FD26118Q59132279-454B0DF2-10C2-46C7-AEEE-42C00710D992
P2860
Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy.
@en
type
label
Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy.
@en
prefLabel
Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy.
@en
P2093
P1433
P1476
Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy.
@en
P2093
Albiruni R Abdul Razak
John Kuruvilla
Lillian L Siu
P304
P356
10.1158/2159-8290.CD-13-1005
P577
2014-04-17T00:00:00Z